CAS-ViewAlert

View Alert


		Versions:

Originator:	CMO Messaging
From:	CMO Messaging
Issue date:	Originally issued on 03-Jun-2020 10:11:47. This version was issued on 03-Jun-2020 10:11:47
This alert has been issued to:
	NHS Foundation Trusts (England) - Medical Director NHS Foundation Trusts (England) - Chief Executive NHS Trusts (England) - Medical Director NHS Trusts (England) - Chief Executive
	MHRA (Medicines) Drug Alerts (Various Recipients) Other contacts Independent Healthcare Providers (registered with CAS) Clinical Commissioning Groups NHS Regional Offices Special Health Authorities CMO Urgent Messages - Non-NHS Recipients on Public Health Link MHRA (Medicines) Drug Alerts - Non-NHS Recipients Territorial CMOs in Northern Ireland, Scotland & Wales Regional Directors of Public Health Consultants in Communicable Diseases CMO Urgent Messages - Recipients on Public Health Link Director of Public Health DHSC Supply Disruption - Medicines
Action category:	Important information for immediate action
Title:	Update - Early Access to Medicines Scheme for remdesivir in the treatment of COVID-19. Implementation of the scheme and management of supply
Broadcast content:	This is an update to the alert we issued on 26 May regarding remdesivir. The access criteria for the remdesivir EAMS have been amended to reflect developing clinical experience and knowledge of demand and changes in medicine supply. For the NHS in England new registrations to the EAMS have now closed: initial stock allocations have been made. Trusts must retrospectively complete a remdesivir Blueteq form to register patients who have received remdesivir in order to receive further medicine supply. Further information can be found in the attached alert.
Additional information:	This alert does not need to be cascaded to primary care.
Alert reference:	CEM/CMO/2020/025(U)
Attachments:	CEM_CMO_2020_025_U_.pdf